Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

• Main Authors: Nestor Szerman (Author), Ignacio Basurte-Villamor (Author), Pablo Vega (Author), Jose Martinez-Raga (Author), Carlos Parro-Torres (Author), Julia Cambra Almerge (Author), Lara Grau-López (Author), Mario De Matteis (Author), Francisco Arias (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone...